Norway Intravenous Iron Drugs Market Size & Outlook
Norway intravenous iron drugs market, 2018-2030 (US$M)
Related Markets
Norway intravenous iron drugs market highlights
- The Norway intravenous iron drugs market generated a revenue of USD 12.6 million in 2023 and is expected to reach USD 23.0 million by 2030.
- The Norway market is expected to grow at a CAGR of 9% from 2024 to 2030.
- In terms of segment, ferric carboxymaltose was the largest revenue generating product in 2023.
- Ferric Carboxymaltose is the most lucrative product segment registering the fastest growth during the forecast period.
Intravenous iron drugs market data book summary
| Market revenue in 2023 | USD 12.6 million |
| Market revenue in 2030 | USD 23.0 million |
| Growth rate | 9% (CAGR from 2023 to 2030) |
| Largest segment | Ferric carboxymaltose |
| Fastest growing segment | Ferric Carboxymaltose |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Iron Dextran, Iron Sucrose, Ferric Carboxymaltose |
| Key market players worldwide | AbbVie Inc, Civitas Resources Inc Ordinary Shares, Daiichi Sankyo Co Ltd, Sanofi SA, CSL Ltd, COSMOS Pharmaceutical Corp, Zydus Lifesciences, Rockwell Medical Inc |
Other key industry trends
- In terms of revenue, Norway accounted for 0.4% of the global intravenous iron drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, France intravenous iron drugs market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 187.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Intravenous Iron Drugs Market Scope
Intravenous Iron Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Norway intravenous iron drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intravenous iron drugs market will help companies and investors design strategic landscapes.
Ferric carboxymaltose was the largest segment with a revenue share of 59.52% in 2023. Horizon Databook has segmented the Norway intravenous iron drugs market based on iron dextran, iron sucrose, ferric carboxymaltose covering the revenue growth of each sub-segment from 2018 to 2030.
According to data published by International Agency for Cancer Research, 2020, around 34,902 new cases of cancer were recorded in Norway. The most common cancer types observed were color ectum, breast, lung, prostate, and stomach.
Rise in the prevalence of cancer and other chronic diseases, such as diabetes & kidney disease, is anticipated to fuel market growth during the forecast period. Norway has major clinics and healthcare settings that provide proper treatment for different target diseases. Moreover, significant reimbursement policies propel the demand for IV iron drugs in the country.
Reasons to subscribe to Norway intravenous iron drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Norway intravenous iron drugs market databook
-
Our clientele includes a mix of intravenous iron drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway intravenous iron drugs market , including forecasts for subscribers. This country databook contains high-level insights into Norway intravenous iron drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Norway intravenous iron drugs market size, by product, 2018-2030 (US$M)
Norway Intravenous Iron Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
